Evidence-based recommendations on upadacitinib (Rinvoq) for treating moderately to severely active ulcerative colitis in adults.
Commercial arrangement
There is a simple discount patient access scheme for upadacitinib. NHS organisations can get details on the Commercial Access and Pricing (CAP) Portal. ...
Chirurgická léčba je součástí péče o pacienty s idiopatickými střevními záněty (IBD). Během prvního roku trvání Crohnovy nemoci (CN) je pravděpodobnost operace 20–40 %, do 10 let je operováno 30–70 % nemocných a po 15 letech od diagnózy 70–90 % nemocných. V prvních deseti let...
This guideline covers using colonoscopy to check for signs of bowel cancer in people aged 18 and over with ulcerative colitis or Crohn’s disease (types of inflammatory bowel disease) or adenomas (also known as polyps). It aims to prevent cancer and prolong life by offering advice on identifying early b...
